Yüklüyor......
Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis
BACKGROUND: Crizotinib show a promising efficacy in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). However, differences in efficacy for first- and second-line crizotinib are unclear. RESULTS: The pooled overall response rate and progression-free survival...
Kaydedildi:
| Yayımlandı: | Oncotarget |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Impact Journals LLC
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5348378/ https://ncbi.nlm.nih.gov/pubmed/27835601 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13191 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|